Wednesday, May 5, 2021

Ivermectin vs. Cancer

This page grew out of my Ivermectin vs. COVID-19 page.  While collecting links on that subject I ran across these papers on ivermectin and cancer.

The drug shows some amazing potential as a safe, non-toxic alternative to chemotherapy.

Papers

Cancers in general.

Ivermectin, a potential anticancer drug derived from an antiparasitic drug

Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin

The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT‐TCF pathway responses in human cancer

Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models

Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug

Inhibition of TMEM16A Ca2+-activated Cl channels by avermectins is essential for their anticancer effects

Ivermectin kills cancer cells via catastrophic changes in the endoplasmic reticulum structure

Old wine in new bottles: Drug repurposing in oncology

Breast Cancer 


Ivermectin converts cold tumors hot and synergies with immune checkpoint blockade for treatment of breast cancer

Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death

Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling

The PAK1-Stat3 Signaling Pathway Activates IL-6Gene Transcription and Human Breast Cancer Stem Cell Formation

Ivermectin as an inhibitor of cancer stem‑like cells

Ovarian Cancer 

The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer

Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine

Ivermectin inactivates the kinase PAK1 and blocks the PAK1- dependent growth of human ovarian cancer and NF2 tumor cell lines

SILAC quantitative proteomics analysis of ivermectin‐related proteomic profiling and molecular network alterations in human ovarian cancer cells

Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling

In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer

Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes

Multiomics-based energy metabolism heterogeneity and its regulation by antiparasite drug ivermectin.

Cervical cancer

Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway 

Oesophageal squamous cell carcinoma (ESCC)

Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma

Renal cancer

Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage

 Glioma 

Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas

Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells

Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress

Nasopharyngeal carcinoma 

Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth

Melanoma

Macrocyclic Lactones Block Melanoma Growth, Metastases Development and Potentiate Activity of Anti–BRAF V600 Inhibitors

Suppressing ROS‐TFE3‐dependent autophagy enhances ivermectin‐induced apoptosis in human melanoma cells

Gastric cancer 

Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer

Liver cancer 

Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice

 Leukemia

Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress

The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells

Clinical Trials

Unfortunately none are listed but keep checking back at the link below.

 List of Ivermectin/Cancer trials at clinicaltrials.gov

Articles

Ivermectin for Parasites, but as a PAK1 Inhibitor for Autism, Cancer and Leukemia?